Selnoflast - Roche
Alternative Names: NLRP3i - Roche; RG 6418; RO-7486967; SomalixLatest Information Update: 28 Aug 2026
At a glance
- Originator Inflazome
- Developer Roche
- Class Anti-inflammatories; Antiasthmatics; Antiparkinsonians; Aromatic hydrocarbons; Piperidines; Small molecules; Urea compounds
- Mechanism of Action NLRP3 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atherosclerosis
- No development reported Asthma; Chronic obstructive pulmonary disease; Inflammation; Parkinson's disease; Ulcerative colitis
Most Recent Events
- 28 Aug 2026 No recent reports of development identified for phase-I development in Asthma in Belgium (PO, Capsule)
- 28 Aug 2026 No recent reports of development identified for phase-I development in Asthma in Canada (PO, Capsule)
- 28 Aug 2026 No recent reports of development identified for phase-I development in Asthma in Germany (PO, Capsule)